Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Irritable Bowel Syndrome
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Irritable Bowel Syndrome
    Amitriptyline as Effective as Placebo for Pain Relief of IBS in Children - (DGNews)
    Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial - (BMJ)
    Patients With IBS Report Similar Satisfaction for Drug Treatments, Alternative Therapies: Presented at DDW - (DGDispatch)
    ACG Publishes Evidence-Based Systematic Review on the Management of IBS - (DGNews)
    Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis - (BMJ)

    News archive

     Recent webcasts/CME - Irritable Bowel Syndrome
    • Latest Data on Individualizing Induction and Maintenance Therapy in Patients With IBD: Selecting Appropriate Treatment Regimens for Optimal Patient Outcomes
    • Considerations for Optimal Selection of Therapy for Patients With Active IBD: Inducing Remission Quickly and Effectively
    • Exploring Maintenance Therapy Strategies in IBD: How Will New Data on Biologics, Combinations, and Postoperative Therapy Impact Practice?
    • Evidence-Based Management of Irritable Bowel Syndrome: A Guide for Primary Care
    • Irritable Bowel Syndrome with Constipation (IBS-C): Improving Patient Care Assessment and Management

      Webcasts/CME archive

       Recent cases - Irritable Bowel Syndrome
        Small Bowel Gastrointestinal Stromal Tumors Can Physiologically Alter Gut Motility Before Causing Mechanical Obstruction
        Irritable Bowel Syndrome
        Dietary Therapy of Irritable Bowel Syndrome

        Cases archive
          




        my personal edition > irritable bowel syndrome > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Rifaximin Helps in the Treatment of Irritable Bowel Syndrome: Presented at ACG

        By Paula Moyer

        HONOLULU, HI -- November 2, 2005 -- Patients with irritable bowel syndrome (IBS) often get relief from one 10-day course of rifaximin (Xifaxan), according to investigators who presented their findings here November 1st at the 70th annual meeting of the American College of Gastroenterology (ACG).

        Rifaximin is currently approved for the treatment of traveler's diarrhea but is often used off-label to treat IBS. The current research was designed to see whether the treatment is effective in the IBS setting.

        "This is the first treatment I've seen for IBS with which the benefit is sustained when the treatment is stopped," said principal investigator Mark Pimentel, MD, Director, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles. "Typically when you stop the treatment, you're right back to baseline."

        Dr. Pimentel and colleagues randomized 87 patients who met Rome I criteria for IBS to receive either placebo or 400 mg of rifaximin orally three times daily for 10 days. During the treatment phase and for 7 days after treatment ended, subjects completed a stool diary and responded to a symptom questionnaire and lactulose breath test. Subjects and investigators were blinded to the test results.

        The 43 patients in the rifaximin group had an average overall symptom improvement of 37.7%, compared to compared to 23.4% of the 44 placebo patients (P < .05). In treatment group, 37% of participants were classified as clinical responders, compared to 16% of those in the placebo group. The study defined response as at least a 50% overall improvement.

        Subjects with diarrhea were more likely than those with constipation to respond to treatment with rifaximin, Dr. Pimentel said. The clinical response among those with diarrhea was 49% for those on rifaximin compared to 23% of those on placebo (P < .05). Bloating was also improved, but not in a statistically significant manner, and the investigators documented no difference in patients with constipation.

        The study was funded by Salix Pharmaceuticals, Ltd., which manufactures Xifaxan.


        [Presentation title: Rifaximin, a Non-Absorbable Antibiotic Improves the Symptoms of Irritable Bowel Syndrome: a Double-Blind Randomized Controlled Study. Abstract 42]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send